The Next Step In A Cure for Stage IV Triple-Negative Breast Cancer is Pam50 And Archetypes

Robert Graham Ph.D. Reporting From New York City US Tennis Open 2012

---

The Next Step In A Cure for Stage IV Triple-Negative Breast Cancer is Pam50 And Archetypes

---

The next step in a cure for Stage IV Triple-Negative Breast Cancer starts with

Gennxeix Pam50 and Archetypes. Yes Archetypal images represent as-yet-unconscious

potentials for a breast cancer patient. Therapy helps patients to relate to archetypal images consciously, thereby releasing their energy for growth.

Brought To You By gloStream How PAM50 Breast Cancer Intrinsic Classifier works. Selene Flores CEO of Gennxeix Biotech says using the PAM50 Breast Cancer Intrinsic Classifier,to show how to characterize error within an MVA, and how these errors may affect results reported

to clinicians. First we estimated the error distribution for measured factors within the PAM50 assay by performing repeated measures on four archetypal samples representative of the major breast cancer tumor subtypes. Then, using the error distributions and the original archetypal sample data, we used Monte Carlo simulations to generate a sufficient number of simulated samples. The effect of these errors on the PAM50 tumor subtype classification was estimated by measuring subtype reproducibility after classifying all simulated samples. Subtype reproducibility was measured as the percentage of simulated samples classified identically to the parent sample. The simulation was thereafter repeated on a large, independent data set of samples from the GEICAM 9906 clinical trial. Simulated samples from the GEICAM sample set were used to explore a more realistic scenario where, unlike archetypal samples, many samples are not easily classified Purpose Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. Patients and Methods In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m2 load then 250 mg/m2 per week intravenously [IV]) alone, with carboplatin (area under the curve of 2, once per week IV) added after progression or as concomitant therapy from the beginning. Response rate (RR) was the primary end point; others included time to progression (TTP), overall survival (OS), and toxicity. Embedded correlative studies included molecular subtyping on archival tissue. Fresh tumor tissue before and after 7 to 14 days of therapy was used for microarray analyses exploring EGFR pathway activity and inhibition. Gennxeix uses Genomics modeling for drivers and passenger math models to locate genes associated with Stage IV Triple-Negative Breast Cancer. The Genes are Luminal B. ✍ BCL2*. ✍ CXXC5. ✍ EGFR*. ✍ KIF2C*. ✍ MDM2*. ✍ MKI67*. ✍ ORC6L*. ✍ PGR*. ✍ PHGDH To take advantage of the full array of options physicians now have with genomics it important that your breast cancer doctors have EMR Electronic Health Records to capture a patients Carl Jung Myers-Briggs Type Indicator (MBTI) scores and provide the breast cancer patient with the best possible care. Gennxeix Similarly, the development of systematic approaches to identify somatic mutations has prompted exhaustive analyses of changes in cancer genomes, including copy-number changes (deletions and amplifications of DNA), rearrangements, small insertions and deletions, and point mutations

What With DNA You can store an Entire Hospital of Patients’ Data in a Device The Size of your Thumb

Robert Graham Ph.D. Reporting From MD Anderson Hospital Houston Medical Center Houston, Texas

---

What With DNA You can store an Entire Hospital of Patients’ Data in a Device The Size of your Thumb

---

Yes it is true scientist and molecular biologists have long known that DNA is a nat

ural information-storage system inside every cell that encodes the recipe for individual heredity. Electronic Medical Records are now is going to be an important part of our lives. The exact order of the DNA bases—which for the average person is a sequence of about three

Houston Please Join Us ---- billion—determines the meaning of the biological instructions stored in genes and chromosomes. DNA contains genetic instructions written in a simple but powerful code made up of four chemicals called bases: adenine (A), guanine (G), cytosine (C) and thymine (T). Gennxeix Biotech Chief Science Officer pointing out to us in a interview at MD Anderson in Houston, Texas that the Harvard researchers started with the digital

version of the book, which is composed of the ones and zeros that computers read. Next, on paper, they translated the zeros into either the A or C of the DNA base pairs, and changed the ones into either the G or T. Then, using now-standard laboratory techniques, they created short strands of actual DNA that held the coded sequence—almost 55,000 strands in all. Each strand contained a portion of the text and an address that indicated where it occurred in the flow of the book. In that form—a viscous liquid or solid salt—a billion copies of the book could fit easily into a test tube and, under normal conditions, last for centuries. Gennxeix science officer says that they are going to do their best to be the first to commercialize this technology. In addition to doing research on DNA storage Gennxeix Biotech is now a reseller of Ion Proton™ Sequencers. Ion Proton™ sequencers, are designed to sequence an entire human genome in a few hours for under $1,000, and can be used to accelerate its research on the genetic mechanisms of breast cancer. The Ion Proton™ Sequencer is a complementary platform to the Ion PGM™ Sequencer, which

has become the fastest selling benchtop sequencer with the largest benchtop next-generation sequencing install base in laboratories worldwide. The Ion PGM™ System remains the fastest and most affordable solution to sequence sets of genes, small genomes and small RNA. The new Ion Proton™ System will deliver rapid, inexpensive sequencing to scientists focused on understanding the function of exomes, transcriptomes and human-scale genomes. There is a growing need for genetic counselors, physicians and other health care providers who are informed about genetics, and electronic support systems to provide

Brought To You By gloStreamaccurate and current information about risk variants. Although patience is said to be a virtue, it is a commodity that many patients cannot afford, since there is much demand for an immediate clinical return on investment in genomics research. However, biology and health care systems are complex, and it is unrealistic to expect that the march of clinical progress will accelerate at the same rate as technological advances. That said, the advances described in the second Genomic Medicine review series show that genomics has made great strides toward improving human health.

What is the Score of The Carl Jung Myers-Briggs Type Indicator (MBTI) For Your Breast Cancer Patients.

Robert Graham Ph.D. Hybrid Medical Media Reporting From New York City New York Wall Street

---

What is the Score of The Carl Jung Myers-Briggs Type Indicator (MBTI) For Your Breast Cancer Patients.

---

What is the Result of The Carl Jung Myers-Briggs Type Indicator (MBTI) For Your Breast

Cancer Patients. Myers-Briggs Type Indicator (MBTI) assessment is a psychometric questionnaire designed to measure psychological preferences in how people perceive the world and make decisions. Now that it is clear that a genomic test for a breast cancer patient will provide data for patients and their families to make decision on positive breast cancer genomics test. Genomics begin with the provision of the human genome sequence in 20001 set in motion several waves of cancer research. The identification of an essentially complete set of protein-coding genes, coupled with the discovery of novel transcribed elements such as microRNAs (see the Glossary), has fostered an explosion of investigation using array-based approaches into patterns of gene expression in most cancer types.

Brought To You By gloStream Similarly, the development of systematic approaches to identify somatic mutations has prompted exhaustive analyses of changes in cancer genomes, including copy-number changes (deletions and amplifications of DNA), rearrangements, small insertions and deletions, and point mutations.2 Recently, these efforts have culminated in the sequencing of complete genomes of human cancers, providing comprehensive catalogues of

somatic mutations.3,4 These studies have yielded insights into the genes that contribute to cellular transformation.2 In parallel, the characterization of inherited variation in human populations has unleashed a surge of exploration into cancer susceptibility, focusing mainly on DNA variants that are common in the general population and that confer small increases in cancer risk. Finally, sets of biologic reagents have been developed that interfere with the function of essentially all genes in living cells, the most widely used being small interfering RNAs. These are being used in myriad ways — for example, to systematically determine which genes are required for cancer cells to survive and which genes confer sensitivity to particular drugs. Gennxeix analytics have shown that breast cancer patients psyche is important when treating the patients cancer. The Patients ego also plays and important role in the elimination of breast cancer. Carl Jung divided the human psyche divided into 3 parts: the ego, the personal unconscious, and the collective unconscious. He is particularly known for his identification of the latter. Jung characterizes these as essentially descending levels of our psyche. The ego is the conscious and thinking self; the personal unconscious is the collective personal experiences unique to each individual, and the collective unconscious is a collection of experiences and behavior patterns that is common to all people. The common experience of practicing oncologists is that only a subgroup of patients with a specific type of breast cancer will derive substantial benefit from a particular therapy. Differences in responses to the same treatment among patients are unsurprising in light of the substantial genomic heterogeneity that exists among tumors. Some of these genomic differences have an important role in determining the likelihood of a clinical

response to treatment. Notably, in instances in which the therapeutic agent is targeted at a particular cellular protein, genomic alterations in the gene encoding that protein can be major determinants of response. For example, overexpression and amplification of HER2 in breast cancer is a strong predictor of benefit from treatment with trastuzumab, an antibody directed against HER2.17 On the basis of such findings, the FDA approved trastuzumab in 1998 for use in the treatment of HER2-amplified metastatic breast cancer. Following this and other examples, most new agents entering clinical trials over the past decade have been postulated to influence pathways important for the proliferation or survival of cancer cells. The genes involved in these cellular pathways are frequently mutated as a consequence of somatic alterations (point mutations, deletions, amplifications, and translocations) known as driver mutations, which directly contribute to the abnormal growth of the cancer cell. As a result, the presence or absence of mutations within these genes can have a profound effect on a patient's response to a specific targeted therapy. To take advantage of the full array of options physicians now have with genomics it important that your breast cancer doctors have EMR Electronic Health Records to capture a patients Carl Jung Myers-Briggs Type Indicator (MBTI) scores and provide the breast cancer patient with the best possible care. Gennxeix Biotech has identify which of the breast cancer gene products and molecular mechanisms that are implicated by sequencing Genomics education for most health care providers is inadequate, and because of the fast-moving nature of the field, there is a paucity of evidence-based guidelines and resources for the vast majority of genomic interventions. Current paradigms for providing genetic services, which were developed to handle rare chromosomal and monogenic conditions, break down in the setting of genomic approaches to more common and etiologically complex conditions.

Protection of Human Subjects of Biomedical and Behavioral Research

Hybrid Medical Media: Reporting From Baylor College Of Medicine Houston, Texas

---

Protection of Human Subjects of Biomedical and Behavioral Research

---

Gennxeix Biotech added Electronic Medical (EMR) Records to it products offering. With the release of EMR Gennxeix Biotech CEO Salene Flores says, We are now able to

comply and achieve higher safety standards for our breast cancer patients, that discover their cancer through genomics and evidence base medicine.

---

Gennxeix ability to sequence human genomes inexpensively raises complex issues concerning the rights and responsibilities of our scientists, health care providers, policymakers, and the public. Although the Health Insurance Portability and Accountability Act (HIPAA), the Americans with Disabilities Act (ADA), and the Genetic Information

Brought To You By gloStream Nondiscrimination Act (GINA) have addressed some of these issues, many issues remain unresolved. Their resolution will be critical to realizing the full benefit of genomic advances. Central to some of these issues is the boundary between research and clinical care, as defined in the Belmont Report produced by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research and the “Common Rule”

that governs much of federally funded biomedical research in the United States.2,3Clearly, further research is needed to identify which of the gene products and molecular mechanisms that are implicated by sequencing and genomewide association studies make good targets for experimental interventions. We have before us several thousand susceptibility variants, mainly identified by such studies. Although each of these variants typically has a small effect and thus is not helpful in predicting risk, the identification of such variants expands our understanding of the biology of human health and disease and implicates specific genes, loci, and pathways in disease susceptibility or progression. Although the translation of knowledge about genes associated with mendelian diseases to interventions has proved more difficult than many observers anticipated, there have been and continue to be many notable successes. These successes are founded on studies such as that described by MacKenzie4 in this issue of the Journal, which establishes an experimental approach to th e treatment of spinal muscular atrophy. The funding of similar research in the context of both rare and complex diseases is critical. Finally, health care providers who request, or are provided with, an analysis of the patient's whole-genome sequence face a nearly insurmountable informational challenge. Genomics education for most health care providers is inadequate, and because of the fast-moving nature of the field, there is a paucity of evidence-based guidelines and resources for the vast majority of genomic interventions. Current paradigms for providing genetic services, which were developed to handle rare chromosomal and monogenic conditions, break down in the setting of genomic approaches to more common and etiologically complex conditions.

Gennxeix

There is a growing need for genetic counselors, physicians and other health care providers who are informed about genetics, and electronic support systems to provide accurate and current information about risk variants.Although patience is said to be a virtue, it is a commodity that many patients cannot afford, since there is much demand for an immediate clinical return on investment in genomics research. However, biology and health care systems are complex, and it is unrealistic to expect that the march of clinical progress will accelerate at the same rate as technological advances. That said, the advances described in the second Genomic Medicine review series show that genomics has made great strides toward improving human health.